Jaykay Enterprises Q1 FY27 Revenue Jumps 35% YoY to ₹74.63 Crore
Jaykay Enterprises reported Q1 FY27 consolidated revenue of ₹74.63 crore, up 35% YoY. Operating EBITDA grew 54% YoY to ₹10.62 crore. The Devanahalli Project is on track for Q4 FY27 commissioning. Medical Implants business is scaling up with positive initial response.
The substantial year-on-year growth in revenue and EBITDA, coupled with positive developments in key business segments like Defence & Aerospace and Medical Implants, indicates a significant positive impact on the company's performance and future prospects.
The company reported significant year-on-year growth in revenue and operating EBITDA, along with positive business highlights and an optimistic management outlook.
Jaykay Enterprises Limited announced its consolidated financial results for the first quarter ended June 30, 2026. The company reported a consolidated revenue of ₹7,463 lakhs (₹74.63 crore), marking a significant 35% year-on-year increase and a 22% quarter-on-quarter growth. Operating EBITDA stood at ₹1,062 lakhs (₹10.62 crore), showing a robust 54% year-on-year rise and a turnaround on a quarter-on-quarter basis.
The Defence & Aerospace segment contributed ₹579 lakhs (₹5.79 crore) in sales with an operating EBITDA of ₹73 lakhs (₹0.73 crore). Key developments in this segment include the certification of Allen Reinforced Plastics Ltd. facilities and progress on the Devanahalli Project, which is slated for commissioning by Q4 FY2026-27.
The Digital Manufacturing segment reported sales of ₹903 lakhs (₹9.03 crore) and operating EBITDA of ₹59 lakhs (₹0.59 crore). The company is focusing on the Medical Implants business, with necessary certifications in place and distribution channels being established, receiving positive initial market feedback. New additive manufacturing products are also being developed for the Defence & Aerospace sector.
The Digital Services segment remained the largest contributor, with sales of ₹5,981 lakhs (₹59.81 crore) and operating EBITDA of ₹930 lakhs (₹9.30 crore).
Mr. Abhishek Singhania, Chairman and Managing Director, expressed optimism about the performance, highlighting the momentum in Defence & Aerospace and the aggressive scaling of the Medical Implants business. He anticipates a robust outlook for the remainder of the year, expecting continued growth in revenues and profitability.
What to do with a filing like this
Jaykay Enterprises Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jaykay Enterprises Limited. Read the original for the full detail.